Exclusive Summary

• - EU-EMA GMP certification and English CTD dossier ready, with Saudi approval and PIC/S progress enabling rapid entry into emerging markets.
• - HER2-positive breast and gastric cancers are global standard-of-care indications listed on the WHO EML, with ~0.5–0.6 million new treatable patients annually.
• - 150 mg vial is launched for routine hospital use, and 440 mg planned in 2027 will cut wastage in higher-weight patients.
• - Typical 30–60% price reduction versus originator supports tender competitiveness and payer savings.
• - Meaningful white space remains in Middle East (beyond KSA), North Africa, parts of Southeast Asia and LatAm, favoring distribution partnerships for fast expansion.

Asset Materials

Contact Us for Full Materials